Metralindole
Source: Wikipedia, the free encyclopedia.
Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
JSmol) | |
| |
Metralindole (Inkazan) is a
reversible inhibitor of monoamine oxidase A (RIMA) which was investigated in Russia as a potential antidepressant.[1] It is structurally and pharmacologically related to pirlindole
.
See also
References
- PMID 1884793.
| ||
|---|---|---|
SNRIs Tooltip Serotonin–norepinephrine reuptake inhibitors | ||
NRIs Tooltip Norepinephrine reuptake inhibitors | ||
NDRIs Tooltip Norepinephrine–dopamine reuptake inhibitors | ||
NaSSAs Tooltip Noradrenergic and specific serotonergic antidepressants | ||
SARIs Tooltip Serotonin antagonist and reuptake inhibitors | ||
SMS Tooltip Serotonin modulator and stimulators | ||
| Others |
| |
TCAs Tooltip Tricyclic antidepressants |
| |
|---|---|---|
TeCAs Tooltip Tetracyclic antidepressants | ||
| Others | ||
| |||||||
|
Miscellaneous | |
|---|---|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III